[ad_1]
Johnson & Johnson’s (JNJ) – Get the report According to a report released Wednesday, the single-injection vaccine candidate has been shown to be safe and generate a significant immune response in an early-phase trial.
A single shot of the vaccine “gives long lasting antibodies,” Dr. Paul Stoffels, scientific director of J&J, told CNBC. The results gave the company “confidence” that the vaccine will be effective, Stoffels told CNBC.
The results of the phase 1-2 trials were published Wednesday in the New England Journal of Medicine.
Johnson & Johnson’s vaccine candidate is also undergoing phase 3 trials to determine its actual effectiveness. The results of this study are expected later this month.
If successful and approved, the vaccine would become the third available to fight the COVID-19 pandemic that continues to spiral out of control in the United States and much of the world.
Almost 400,000 Americans have died from the disease and more than 22 million have been infected.
A vaccine jointly developed by Pfizer (PFE) – Get the report and BioNTech (BNTX) – Get the report got emergency use approval last month with a second vaccine from Moderna (RNAm) – Get the report. Both require follow-up booster injections and are stored at very low temperatures, making vaccine distribution and deployment difficult. The United States is significantly behind schedule against planned immunization schedules which called for the administration of 20 million vaccines by the end of December. So far, only around 10 million have done so.
The Johnson and Johnson vaccine requires only one injection and can be stored at higher temperatures. However, its rollout is also behind schedule and likely won’t begin until April, due to manufacturing delays, assuming it is cleared for use by the FDA.
Johnson and Johnson shares rose 1.08% to $ 159.60 after hours on Wednesday.
[ad_2]
Source link